2h
Zacks Investment Research on MSNWhy Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 1.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...
4h
Zacks Investment Research on MSNCan BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...
Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST] ...
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...
Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...
The stock's fall snapped a seven-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results